Takeda Gets Actos Case Paused For Class Cert. Review

By Matthew Perlman · April 14, 2025, 3:55 PM EDT

A New York federal court has paused a lawsuit accusing Takeda Pharmaceuticals of inflating the price of its diabetes treatment, Actos, by delaying the entry of generic alternatives, and took a...

To view the full article, register now.

Try a seven day FREE Trial

Already a subscriber? Click here to login

Documents

Order

Case Information

Case Title

In re ACTOS Antitrust Litigation

Case Number

1:13-cv-09244

Court

New York Southern

Nature of Suit

Contract: Other

Date Filed

December 31, 2013

Case Title

In Re: ACTOS Antitrust Litigation

Case Number

24-2749

Court

Appellate - 2nd Circuit

Nature of Suit

Date Filed

October 18, 2024

Recent Articles By Matthew

June 16, 2025
Ohio Tells 6th Circ. PBM Case Doesn't Target Federal Work
June 13, 2025
Injunction Sought After J&J Unit's Catheter Antitrust Loss
June 12, 2025
Florida, Sandoz Say They've Fixed Generic Drug Price-Fix Deal
June 10, 2025
Health Records Co. Looks To Toss Patient Data Access Case
June 02, 2025
Monthly Merger Review Snapshot
May 23, 2025
FTC Probing Alcon's $430M Lensar Deal
May 15, 2025
Hillrom Says Missing Attachment Could End Antitrust Case
May 14, 2025
Total Vision Reaches Deal Ending VSP Antitrust Case
May 13, 2025
FTC To Keep Focus On Key Sectors, Address Personal Liberty
May 09, 2025
Pathology Lab Urges 8th Circ. Not To Revive Antitrust Claims

Takeda Gets Actos Case Paused For Class Cert. Review

Documents

Related Sections

Case Information

Case Title

Case Number

Court

Nature of Suit

Date Filed

Case Title

Case Number

Court

Nature of Suit

Date Filed

Recent Articles By Matthew